



A nonprofit corporation and independent licensee of the Blue Cross and Blue Shield Association

Medical Oncology Program

For BCN HMOSM (commercial) members

Effective August 1, 2019

Blue Care Network manages medical oncology and supportive care drugs. Prior to August 1, 2019, many medical oncology drugs required authorization from BCN via Novologix. Effective August 1, 2019, authorizations are required through AIM Specialty Health. Authorization requests must be submitted to AIM prior to drugs being administered for payment. The medical oncology drug management program is only for drugs with oncology indications.

HCPCS	Generic Name	Brand Name	Effective Date	End Date
J9264	Paclitaxel Protein-Bound Particles	Abraxane	8/1/2019	
J9042	Brentuximab Vedotin	Adcetris	8/1/2019	
J9305	Pemetrexed Disodium	Alimta	8/1/2019	
J9057	Copanlisib HCl	Aliqopa	8/1/2019	
J9302	Ofatumumab	Arzerra	8/1/2019	
J9118	Calaspargase Pegol-mknl	Asparlas	11/1/2019	
J9035	Bevacizumab	Avastin	8/1/2019	
J9023	Avelumab	Bavencio	8/1/2019	
J9036	Bendamustine HCl	Belrapzo	11/1/2019	
J9034	Bendamustine HCl	Bendeka	8/1/2019	
J9229	Inotuzumab Ozogamicin	Besponsa	8/1/2019	
J9039	Blinatumomab	Blinicyto	8/1/2019	
J9308	Ramucirumab	Cyramza	8/1/2019	
J9145	Daratumumab	Darzalex	8/1/2019	
J3490, J3590, J9999	Daratumumab and Hyaluronidase-fihj	Darzalex Faspro	7/24/2020	
Q2049, Q2050	Doxorubicin Liposomal	Doxil, Lipodox	8/1/2019	
J9269	Tagraxofusp-erzs	Elzonris	11/1/2019	
J9176	Elotuzumab	Empliciti	8/1/2019	
J9358	Fam-trastuzumab Deruxtecan-nxki	Enhertu	3/2/2020	
J9055	Cetuximab	Erbix	8/1/2019	
J9245	Melphalan	Evomela	8/1/2019	6/30/2020
J9246	Melphalan	Evomela	7/1/2020	
Q5108	Pegfilgrastim-jmdb	Fulphila	8/1/2019	
J0641	Levoleucovorin	Fusilev	8/1/2019	
J9301	Obinutuzumab	Gazyva	8/1/2019	
J1447	Tbo-Filgrastim	Granix	8/1/2019	
J9179	Eribulin	Halaven	8/1/2019	
J9355	Trastuzumab	Herceptin	8/1/2019	

Blue Care Network manages medical oncology and supportive care drugs. Prior to August 1, 2019, many medical oncology drugs required authorization from BCN via Novologix. Effective August 1, 2019, authorizations are required through AIM Specialty Health. Authorization requests must be submitted to AIM prior to drugs being administered for payment. The medical oncology drug management program is only for drugs with oncology indications.

HCPCS	Generic Name	Brand Name	Effective Date	End Date
J9356	Trastuzumab and Hyaluronidase- oysk	Herceptin Hylecta	11/1/2019	
Q5113	Trastuzumab-pkrb	Herzuma	11/1/2019	
J9173	Durvalumab	Imfinzi	8/1/2019	
J9325	Talimogene Laherparepvec	Imlygic	8/24/2020	
J9315	Romidepsin	Istodax	8/1/2019	
J9207	Ixabepilone	Ixempra	8/1/2019	
J3490, J3590, J9999	Mitomycin	Jelmyto	7/24/2020	
J9043	Cabazitaxel	Jevtana	8/1/2019	
J9354	Ado-Trastuzumab	Kadcyla	8/1/2019	
Q5117	Trastuzumab-anns	Kanjinti	11/1/2019	
J9271	Pembrolizumab	Keytruda	8/1/2019	
J0642	Levoleucovorin	Khapzory	8/1/2019	
J9047	Carfilzomib	Kyprolis	8/1/2019	
J2820	Sargramostim	Leukine	8/1/2019	
J9119	Cemiplimab-rwic	Libtayo	10/1/2019	
J9313	Moxetumomab Pasudotox-tdfk	Lumoxiti	10/1/2019	
J2562	Plerixafor	Mozobil	8/1/2019	
Q5107	Bevacizumab-awwb	Mvasi	8/1/2019	
J9203	Gemtuzumab Ozogamicin	Mylotarg	8/1/2019	
J2505	Pegfilgrastim	Neulasta; Neulasta OnPro	8/1/2019	
J1442	Filgrastim	Neupogen	8/1/2019	
Q5110	Filgrastim-aafi	Nivestym	8/1/2019	
J3490, J3590, J9999	Pegfilgrastim-apgf	Nyvepria	9/25/2020	
Q5114	Trastuzumab-dkst	Ogivri	11/1/2019	



A nonprofit corporation and independent licensee of the Blue Cross and Blue Shield Association

Medical Oncology Program

For BCN HMOSM (commercial) members

Effective August 1, 2019

Blue Care Network manages medical oncology and supportive care drugs. Prior to August 1, 2019, many medical oncology drugs required authorization from BCN via Novologix. Effective August 1, 2019, authorizations are required through AIM Specialty Health. Authorization requests must be submitted to AIM prior to drugs being administered for payment. The medical oncology drug management program is only for drugs with oncology indications.

HCPCS	Generic Name	Brand Name	Effective Date	End Date
J9205	Irinotecan Liposome	Onivyde	8/1/2019	
Q5112	Trastuzumab-dttb	Ontruzant	11/1/2019	
J9299	Nivolumab	Opdivo	8/1/2019	
J9177	Enfortumab Vedotin-ejfv	Padcev	3/2/2020	
J9306	Pertuzumab	Perjeta	8/1/2019	
J3490, J3590, J9999	Pertuzumab, Trastuzumab and Hyaluronidase-zzxf	Phesgo	9/25/2020	
J9309	Polatuzumab Vedotin-piiq	Polivy	11/1/2019	
J9295	Necitumumab	Portrazza	8/1/2019	
J9204	Mogamulizumab-kpkc	Poteligeo	8/1/2019	
Q2043	Sipuleucel-T	Provenge	8/1/2019	
J9311	Rituximab-Hyaluronidase Human	Rituxan Hycela	8/1/2019	
J3490, J3590, J9999	Isatuximab-irfc	Sarclisa	5/15/2020	
J2860	Siltuximab	Sylvant	8/1/2019	
J9022	Atezolizumab	Tecentriq	8/1/2019	
Q5116	Trastuzumab-gyyp	Trazimera	11/1/2019	
J9033	Bendamustine HCl	Treanda	8/1/2019	
J3490, J3590, J9999	Sacituzumab Govitecan-hziy	Trodelvy	7/24/2020	
Q5111	Pegfilgrastim-cbqv	Udenyca	8/1/2019	
J3490, J3590, J9999	Dinutuximab	Unituxin	8/1/2019	
J9303	Panitumumab	Vectibix	8/1/2019	
J9228	Ipilimumab	Yervoy	8/1/2019	
J9352	Trabectedin	Yondelis	8/1/2019	
J9400	Ziv-Aflibercept	Zaltrap	8/1/2019	
Q5101	Filgrastim-sndz	Zarxio	8/1/2019	



A nonprofit corporation and independent licensee of the Blue Cross and Blue Shield Association

Medical Oncology Program

For BCN HMOSM (commercial) members

Effective August 1, 2019

Blue Care Network manages medical oncology and supportive care drugs. Prior to August 1, 2019, many medical oncology drugs required authorization from BCN via Novologix. Effective August 1, 2019, authorizations are required through AIM Specialty Health. Authorization requests must be submitted to AIM prior to drugs being administered for payment. The medical oncology drug management program is only for drugs with oncology indications.

HCPCS	Generic Name	Brand Name	Effective Date	End Date
J3490, J3590, J9999	Lurbinectedin	Zepzelca	9/25/2020	
Q5120	Pegfilgrastim-bmez	Ziextenzo	2/5/2020	
Q5118	Bevacizumab-bvzr	Zirabev	11/1/2019	